Haleon plc (HLNCF) Stock Price & Analysis
Haleon plc (HLNCF) — price $4.52 (-0.88%), as of the Nov 19, 2026 trading session; market cap $39.6B.
Educational signal · not a buy or sell recommendation · How to read this
Haleon plc · HLNCF · Healthcare · Drug Manufacturers - Specialty & Generic
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.52 | |
| Change on the day | -0.88% | |
| 52-week range | $4.15–$5.75 | |
| Market capitalisation | $39.6B | — |
| Price / earnings (trailing) | 18.87 | |
| Shares traded on the day | 1.0K | |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Haleon (HLNCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Haleon (HLNCF), and what does it report?
Short answer
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: Building 5, First Floor, THE Heights, Weybridge, X0, KT13 0NY. It employs 24,561 people and is led by Brian James McNamara. In Q2 FY2025 it reported revenue of £2.74B and net income of £403M. The market values it at $39.6B.
What do the latest results show for Haleon (HLNCF)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of £2.74B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | £2.74B | £403M | £0.04 (diluted) |
| Q1 FY2025 | £2.74B | £403M | £0.04 (diluted) |
| Q4 FY2024 | £2.76B | £231M | £0.03 (diluted) |
| Q3 FY2024 | £2.78B | £485M | £0.05 (diluted) |
What are the financial strengths and risks for Haleon (HLNCF)?
Short answer · as of
The distress and quality screens read Altman Z 2.88 · Piotroski F 7. Trailing ratios: ROE 10.1% · ROA 5.1% · current ratio 0.69.
What should you watch next at Haleon (HLNCF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $11.32B · EPS 0.21 · 16 analysts.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q2 FY2025) was filed Jun 30, 2025 — 8 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $11.32B
- EPS estimate
- $0.21
Measured against a quoted price of $4.52 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HLNCF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HLNCF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Haleon (HLNCF)?
What Investors Ask About Haleon (HLNCF) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Why does Haleon appear under drug manufacturers when it owns Sensodyne and Centrum?
The classification groups Haleon with specialty and generic drug producers, but its operating description is that of a global consumer healthcare company. Sensodyne, Centrum, Panadol, and its related brands generate sales through consumer health categories supported by production, distribution, and marketing.
How do Panadol, Voltaren, and Advil fit Haleon’s model?
They anchor Haleon’s pain-management offering within a broader portfolio that also covers oral health, respiratory care, digestive health, and supplements. Their role is to turn Haleon’s research, manufacturing, distribution, and promotional capabilities into repeat consumer demand across markets.
What is the HLNCF stock price today?
The last price recorded for Haleon plc (HLNCF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 23 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com